298 related articles for article (PubMed ID: 15068398)
41. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.
LoRusso PM; Herbst RS; Rischin D; Ranson M; Calvert H; Raymond E; Kieback D; Kaye S; Gianni L; Harris A; Bjork T; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Feyereislova A; Heyes A; Averbuch SD; Ochs J; Baselga J
Clin Cancer Res; 2003 Jun; 9(6):2040-8. PubMed ID: 12796366
[TBL] [Abstract][Full Text] [Related]
42. The role of gefitinib in lung cancer treatment.
Giaccone G
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4233s-4237s. PubMed ID: 15217964
[TBL] [Abstract][Full Text] [Related]
43. Effects of ZD1839 (Iressa, gefitinib) treatment on symptoms and quality of life in patients with advanced non-small cell lung cancer.
Natale RB
Semin Oncol; 2004 Jun; 31(3 Suppl 9):23-30. PubMed ID: 15206079
[TBL] [Abstract][Full Text] [Related]
44. Clinically meaningful response to the EGFR tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in non small cell lung cancer.
Gelibter A; Ceribelli A; Milella M; Mottolese M; Vocaturo A; Cognetti F
J Exp Clin Cancer Res; 2003 Sep; 22(3):481-5. PubMed ID: 14582710
[TBL] [Abstract][Full Text] [Related]
45. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
Fukuoka M; Yano S; Giaccone G; Tamura T; Nakagawa K; Douillard JY; Nishiwaki Y; Vansteenkiste J; Kudoh S; Rischin D; Eek R; Horai T; Noda K; Takata I; Smit E; Averbuch S; Macleod A; Feyereislova A; Dong RP; Baselga J
J Clin Oncol; 2003 Jun; 21(12):2237-46. PubMed ID: 12748244
[TBL] [Abstract][Full Text] [Related]
46. Lessons from the ("Iressa" Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations.
Stahel R; Rossi A; Petruzelka L; Kosimidis P; de Braud F; Bernardo MM; Souquet PJ; Parra HS; Gridelli C
Br J Cancer; 2003 Dec; 89 Suppl 2(Suppl 2):S19-23. PubMed ID: 14661049
[TBL] [Abstract][Full Text] [Related]
47. Gefitinib: phase II and III results in advanced non-small cell lung cancer.
Kelly K; Averbuch S
Semin Oncol; 2004 Feb; 31(1 Suppl 1):93-9. PubMed ID: 14981586
[TBL] [Abstract][Full Text] [Related]
48. Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer.
Yokouchi H; Yamazaki K; Kinoshita I; Konishi J; Asahina H; Sukoh N; Harada M; Akie K; Ogura S; Ishida T; Munakata M; Dosaka-Akita H; Isobe H; Nishimura M
BMC Cancer; 2007 Mar; 7():51. PubMed ID: 17374153
[TBL] [Abstract][Full Text] [Related]
49. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer.
Adjei AA; Molina JR; Mandrekar SJ; Marks R; Reid JR; Croghan G; Hanson LJ; Jett JR; Xia C; Lathia C; Simantov R
Clin Cancer Res; 2007 May; 13(9):2684-91. PubMed ID: 17473200
[TBL] [Abstract][Full Text] [Related]
50. Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?
Rukazenkov Y; Speake G; Marshall G; Anderton J; Davies BR; Wilkinson RW; Mark Hickinson D; Swaisland A
Anticancer Drugs; 2009 Nov; 20(10):856-66. PubMed ID: 19657272
[TBL] [Abstract][Full Text] [Related]
51. Phase I studies of ZD1839 in patients with common solid tumors.
Lorusso PM
Semin Oncol; 2003 Feb; 30(1 Suppl 1):21-9. PubMed ID: 12644981
[TBL] [Abstract][Full Text] [Related]
52. Overview of gefitinib in non-small cell lung cancer: an Asian perspective.
Jiang H
Jpn J Clin Oncol; 2009 Mar; 39(3):137-50. PubMed ID: 19088154
[TBL] [Abstract][Full Text] [Related]
53. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
Herbst RS; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Baselga J; Rojo F; Hong WK; Swaisland H; Averbuch SD; Ochs J; LoRusso PM
J Clin Oncol; 2002 Sep; 20(18):3815-25. PubMed ID: 12228201
[TBL] [Abstract][Full Text] [Related]
54. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer.
Parra HS; Cavina R; Latteri F; Zucali PA; Campagnoli E; Morenghi E; Grimaldi GC; Roncalli M; Santoro A
Br J Cancer; 2004 Jul; 91(2):208-12. PubMed ID: 15187994
[TBL] [Abstract][Full Text] [Related]
55. ZD1839 ('Iressa') as an anticancer agent.
Baselga J; Averbuch SD
Drugs; 2000; 60 Suppl 1():33-40; discussion 41-2. PubMed ID: 11129170
[TBL] [Abstract][Full Text] [Related]
56. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets.
Cohen MH; Williams GA; Sridhara R; Chen G; McGuinn WD; Morse D; Abraham S; Rahman A; Liang C; Lostritto R; Baird A; Pazdur R
Clin Cancer Res; 2004 Feb; 10(4):1212-8. PubMed ID: 14977817
[TBL] [Abstract][Full Text] [Related]
57. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
Baselga J; Rischin D; Ranson M; Calvert H; Raymond E; Kieback DG; Kaye SB; Gianni L; Harris A; Bjork T; Averbuch SD; Feyereislova A; Swaisland H; Rojo F; Albanell J
J Clin Oncol; 2002 Nov; 20(21):4292-302. PubMed ID: 12409327
[TBL] [Abstract][Full Text] [Related]
58. ZD1839 (Iressa): what's in it for the patient?
Natale RB; Zaretsky SL
Oncologist; 2002; 7 Suppl 4():25-30. PubMed ID: 12202785
[TBL] [Abstract][Full Text] [Related]
59. Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report.
Padda SK; Chhatwani L; Zhou L; Jacobs CD; Lopez-Anaya A; Wakelee HA
Anticancer Drugs; 2013 Aug; 24(7):731-5. PubMed ID: 23552470
[TBL] [Abstract][Full Text] [Related]
60. Bilateral subdural hemorrhage as a possible adverse event of gefitinib in a patient with non-small cell lung cancer.
Kim JH; Kim HS; Choi JS; Lee KM; Shin YC; Ahn BM; Choi DR; Kwon JH; Park S; Kim HY; Jung JY; Kim HJ; Song HH; Zang DY
Lung Cancer; 2009 Apr; 64(1):121-3. PubMed ID: 19022521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
